Clinical trials: sponsored by Bristol-Myers Squibb
HIV Infections, Leukoencephalopathy, Progressive Multifocal
A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine
The objective of this open-label study regimen is to make didanosine (ddI) available to patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the Phase II ddI programs due to protocol exclusion…
- Trial name
- NCT00002274
- Testing
- Didanosine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections, Chickenpox
A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.
- Trial name
- NCT00002358
- Testing
- Sorivudine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
The objective of this treatment IND protocol is to make didanosine (ddI) available to patients with HIV infection (suffering from AIDS related complex (ARC) or AIDS) who have developed documented intolerance to zidovudine (AZT)…
- Trial name
- NCT00002028
- Testing
- Didanosine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
- Trial name
- NCT00002234
- Testing
- Efavirenz, Adefovir dipivoxil, Lamivudine
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences